Strong sales growth and strategic …

• Total turnover: USD 66.8 million for the first quarter, an increase of 12% compared to the first quarter of 2024.

• Income from subscription software: USD 32.2 million in the first quarter, 30% compared to the previous year.

• Gross marge: 52.8% in the first quarter, an increase of 4.3 percentage points compared to the fourth quarter.

• Adapted EBITDA: Negative $ 12.2 million, improves from negative $ 45.6 million in the first quarter of 2024.

• Cash and marketable securities: 222 million US dollars at the end of the first quarter, without debt.

• F&E editions: USD 22.1 million, a decline of 17% compared to the first quarter of 2024.

• Sales and marketing costs: $ 12.6 million, 51% lower than cross section 2024.

• G&A editions: USD 23.2 million, 29% lower than Q1 2024.

• Visit income: USD 26.6 million, 14.3% lower than in the previous year, but after normalizing APC by 6.6% higher.

• Average sales per visit: $ 71, 8% lower than Q1 2024, but 8% higher after normalization for APC.

• Q2 income instructions: Is expected to be in the range of 62 to 67 million US dollars.

• Q2 adapted EBITDA instructions: Probably in the area of ​​negative 12 to 10 million US dollars.

• 2025 sales advice: Is expected to be in the range of 250 to 260 million US dollars.

• 2025 adapted EBITDA instructions: Probably in the area of ​​negative 55 to 45 million US dollars.

Appearance date: May 1, 2025

You can find the complete copy of the earnings call in the complete earnings call.

• American Well Corp (NYSE: AMWL) reported on a strong start by 2025 with significant progress in achieving a positive cash flow from business until 2026.

• In its partnership with the military health system, the company made significant progress and positioned itself as important contributors in the federal market landscape.

• The AMWL software turnover rose over 30%compared to the first quarter of last year, which is due to strategic customer deployments.

• The company successfully increased its mixture of income from subscription software and aimed at a sensible margin extension this year.

• The AMWL platform reported a high level of satisfaction of the patients and the provider with a results of well over 90%.

• The deployment time of the automated and digital behavioral health programs from AMWL was delayed to the third quarter due to management crossings at DHA.

• The company recorded a decrease in visits 23%compared to the previous year, which is due to a decline in sales.

• The average sales per visit decreased by 8% compared to the first quarter of last year.

• The adapted EBITDA from AMWL remains negative, although it has improved compared to the previous year.

• There is uncertainty about the renewal of the DHA contract, which is of crucial importance for the future sales projections of AMWL.

Q: Outside of the DHA, can you talk about booking trends for the convergent and the effects of the attitude of Dan from Amazon? A: We see a strong receptivity for the Amwell platform beyond the DHA, whereby the understanding grows that more people are looked after online. Dan, who took part in Amazon, brings specialist knowledge in AI and platform services in order to optimize consumers' experiences and improve data analyzes.